innovation

MIRAVA Launches Smartboat in Europe with $5M Angel Funding

Cannes – – September 09, 2026 -- MIRAVA, a smartboat developer, has secured $5 million in angel funding to launch its debut model in Europe after three years of product development. The company will unveil its 7.9-meter smartboat at the Cannes Yachting Festival 2026, marking its first European market entry.

MIRAVA raises $5 million to fund production and small-series delivery

The angel round will support continued product development, manufacturing and delivery of the boat in limited quantities as MIRAVA prepares for its next commercialization phase. The company spent three years developing the platform, focusing on making advanced maritime technology practical rather than simply adding features.

Nanochon Treats First Patient in Chondrograft Knee Cartilage Trial

Baltimore – September 07, 2026 -- Nanochon, Inc. has completed the first procedure in its First-in-Human clinical study for ChondrograftTM, a 3D-printed implant targeting articular cartilage defects of the knee, with the surgery performed at The Panama Clinic in Panama City.

Drs. Osorio and Tufiño perform first Chondrograft implant procedure in Panama

Dr. Juan Osorio, the study's Principal Investigator, and Dr. Emilio Tufiño, both specialists in regenerative sports medicine, carried out the bone-sparing, minimally invasive procedure. Dr. Tufiño noted the dedicated instrumentation set made the operation simple and efficient.

Fosun International Profit Jumps 160.3% to RMB1.72 Billion in H1 2026

HONG KONG -- September 01, 2026 -- Fosun International reported a 160.3% year-on-year surge in first-half profit attributable to owners of the parent to RMB1.72 billion, the conglomerate said at an interim results presentation held in Hong Kong on Aug. 28. Total revenue for the six-month period reached RMB86.96 billion, with overseas markets contributing RMB49.16 billion, or 56.5% of the total. The briefing marked Fosun's first in-person results presentation in Hong Kong in six years, attended by Chairman Guo Guangchang, Co-Chairman Wang Qunbin, Co-CEOs Chen Qiyu and Xu Xiaoliang, and CFO Gong Ping.

Four Core Units Generate 73.5% of Group Revenue

Fosun Pharma, Yuyuan, Portuguese insurer Fidelidade, and the group's tourism segment together accounted for 73.5% of total revenue in the first half, the company disclosed. Pharmaceutical and insurance operations delivered the strongest performance among the four units.